Morgan Stanley
APGE icon

Morgan Stanley’s Apogee Therapeutics APGE Stock Holding History

Morgan Stanley’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$189M Buy
1,421,681
+826,649
+139% +$74.5M 0.01% 1082
2026
Q1 		$50.1M Sell
595,032
-295,232
-33% -$21.4M ﹤0.01% 2094
2025
Q4 		$67.2M Buy
890,264
+425,301
+91% +$26.8M ﹤0.01% 1802
2025
Q3 		$18.5M Sell
464,963
-9,739
-2% -$372K ﹤0.01% 2958
2025
Q2 		$20.6M Sell
474,702
-45,237
-9% -$1.72M ﹤0.01% 2769
2025
Q1 		$19.4M Buy
519,939
+310,405
+148% +$12M ﹤0.01% 2723
2024
Q4 		$9.49M Sell
209,534
-28,736
-12% -$1.47M ﹤0.01% 3456
2024
Q3 		$14M Buy
238,270
+3,490
+1% +$167K ﹤0.01% 3148
2024
Q2 		$9.24M Buy
234,780
+98,642
+72% +$4.79M ﹤0.01% 3385
2024
Q1 		$9.05M Buy
136,138
+68,439
+101% +$2.99M ﹤0.01% 3428
2023
Q4 		$1.89M Buy
67,699
+36,217
+115% +$726K ﹤0.01% 4540
2023
Q3 		$671K Buy
+31,482
New +$694K ﹤0.01% 5015

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Morgan Stanley's APGE Position: Q2 2026 in Review

Morgan Stanley increased its Apogee Therapeutics (APGE) stake by 139% in Q2 2026, buying an estimated $74.5M and bringing the position to 1,421,681 shares worth $189M. The position accounts for 0.01% of the portfolio, ranked #1082.

Morgan Stanley first reported a position in APGE in Q3 2023 and has held it in 12 quarters since. 288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Morgan Stanley held 1,421,681 shares of Apogee Therapeutics worth $189M as of Q2 2026.
  • Morgan Stanley bought 826,649 Apogee Therapeutics shares in Q2 2026, an estimated $74.5M.
  • Apogee Therapeutics made up 0.01% of Morgan Stanley's portfolio in Q2 2026, its #1082 holding.
  • Morgan Stanley first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • 288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.